Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 6, 2023; 11(22): 5309-5315
Published online Aug 6, 2023. doi: 10.12998/wjcc.v11.i22.5309
Published online Aug 6, 2023. doi: 10.12998/wjcc.v11.i22.5309
Anti-phospholipase A2 receptor-associated membranous nephropathy with human immunodeficiency virus infection treated with telitacicept: A case report
Jin-Ling Wang, Yan-Ling Sun, Zhe Kang, Sheng-Kun Zhang, Chun-Xin Yu, Wan Zhang, Hua Xie, Department of Nephrology, Dalian Renal Care Hospital, Dalian 116000, Liaoning Province, China
Hong-Li Lin, Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Dalian 116000, Liaoning Province, China
Author contributions: Wang JL, Sun YL, Kang Z, Zhang SK, Yu CX, Zhang W, and Xie H participated in the acquisition of clinical data; Lin HL, Wang JL, Sun YL, and Xie H carried out analysis of patient’s clinical course and data interpretation; Wang JL and Lin HL wrote a draft of the manuscript; Sun YL and Kang Z prepared figures; Zhang SK, Yu CX, Zhang W, and Xie H revised it critically; All authors read and approved the final manuscript.
Informed consent statement: The informed consent form was signed by patient.
Conflict-of-interest statement: The authors declare that there were no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong-Li Lin, PhD, Chief Physician, Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian 116000, Liaoning Province, China. linhongli1216@163.com
Received: March 2, 2023
Peer-review started: March 2, 2023
First decision: June 12, 2023
Revised: July 7, 2023
Accepted: July 17, 2023
Article in press: July 17, 2023
Published online: August 6, 2023
Peer-review started: March 2, 2023
First decision: June 12, 2023
Revised: July 7, 2023
Accepted: July 17, 2023
Article in press: July 17, 2023
Published online: August 6, 2023
Core Tip
Core Tip: The clinical management of anti-phospholipase A2 receptor-associated membranous nephropathy concurrent with human immunodeficiency virus infection presents significant challenges, primarily due to potential unregulated immune responses. In this report, we demonstrated that a weekly subcutaneous injection of telitacicept (160 mg) could ameliorate the 24-h urinary protein levels and enhance serum albumin concentrations, with no discernible impact on T cell counts, showcasing its safety profile.